Celldex Therapeutics, Inc. (CLDX)

Market Cap	1.49B
Revenue (ttm)	9.98M
Net Income (ttm)	-154.08M
Shares Out	66.34M
EPS (ttm)	-2.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	465,659
Open	22.90
Previous Close	22.59
Day's Range	22.42 - 23.37
52-Week Range	20.91 - 53.18
Beta	1.60
Analysts	Buy
Price Target	61.86 (+175.42%)
Earnings Date	Mar 4, 2025

About CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 10, 2008
• Employees: 160
• Stock Exchange: NASDAQ
• Ticker Symbol: CLDX
• Website: https://www.celldex.com

Financial Performance

In 2023, Celldex Therapeutics's revenue was $6.88 million, an increase of 192.02% compared to the previous year's $2.36 million. Losses were -$141.43 million, 25.9% more than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for CLDX stock is "Buy." The 12-month stock price forecast is $61.86, which is an increase of 175.42% from the latest price.

Price Target

$61.86

(175.42% upside)

Analyst Consensus: Buy